Powered by

Amgen taps Provention Bio to develop celiac disease drug

Nov 06, 2018 - FierceBiotech

Provention Bio has licensed a celiac disease drug from Amgen. Under the deal, the New Jersey-based biotech will take over the drug's development, picking up a $20 million investment from Amgen and, potentially, a $150 million phase 2b payout.

Amgen originally developed AMG 714, a human immunoglobulin monoclonal antibody, for rheumatoid arthritis before testing it out in celiac disease. In 2015, the Big Pharma licensed it to Celimmune, which carried out two phase 2 trials, in celiac disease...